Medtech Report

Medtech’s VC exits get a clean bill of health

Exits in medtech picked up in Q3 after a slow, tough period. And the number of acquisitions has seen a rise, with companies like Endomag and Paragonix getting bought for more than $100 million. The quarter also saw the largest VC deal to date, Element Biosciences' $277 million Series D in July. And despite a dip in Q3, deal flow is still on track to surpass 2023’s figure by 17%.

PitchBook’s latest Emerging Tech Research plots what is next for the vertical. Touching on the trends and segments generating excitement and capital, the Q3 Medtech Report also examines companies experimenting with smart implant and wound care technology, both areas seeing a wave of investment.